Cartesian's Descartes-08 retreatment cuts MG-ADL 6.6 points at Month 12; no new safety signals; Phase 3 AURORA data 1Q27

Cartesian Therapeutics, Inc.

In 5 retreated MG patients, mean MG-ADL fell 6.6 (±4.2) points and MGC fell 15 (±6.2) points from baseline at Month 12 after retreatment.
Median time from initial treatment completion to first retreatment was 16.6 months; all patients had clinically meaningful MGC (≥3) and MG-ADL (≥2) reductions.
No serious adverse events during retreatment; no cases of CRS, ICANS, cytopenias, or hypogammaglobulinemia; adverse events were transient and mild.
Phase 3 AURORA topline data expected 1Q27; BLA filing in MG expected mid-2027; Descartes-08 has RMAT and Orphan Drug designations and FDA SPA agreement.
Patients had mean disease duration of 13 years and extensive prior treatment histories.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.